Researchers improved the specificity and persistent antitumor activity of therapeutic T cells with synthetic Notch CAR circuits.
[Science Translational Medicine]
6445218 {6445218:93IRUWLN} apa 50 1 161716 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-e2666dd383115e6217157c86737ca2c8%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%2293IRUWLN%22%2C%22library%22%3A%7B%22id%22%3A6445218%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hyrenius-Wittsten%20et%20al.%22%2C%22parsedDate%22%3A%222021-04-28%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EHyrenius-Wittsten%2C%20A.%2C%20Su%2C%20Y.%2C%20Park%2C%20M.%2C%20Garcia%2C%20J.%20M.%2C%20Alavi%2C%20J.%2C%20Perry%2C%20N.%2C%20Montgomery%2C%20G.%2C%20Liu%2C%20B.%2C%20%26amp%3B%20Roybal%2C%20K.%20T.%20%282021%29.%20SynNotch%20CAR%20circuits%20enhance%20solid%20tumor%20recognition%20and%20promote%20persistent%20antitumor%20activity%20in%20mouse%20models.%20%3Ci%3EScience%20Translational%20Medicine%3C%5C%2Fi%3E%2C%20%3Ci%3E13%3C%5C%2Fi%3E%28591%29.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fscitranslmed.abd8836%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fscitranslmed.abd8836%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445218%26amp%3Bitem_key%3D93IRUWLN%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22SynNotch%20CAR%20circuits%20enhance%20solid%20tumor%20recognition%20and%20promote%20persistent%20antitumor%20activity%20in%20mouse%20models%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Axel%22%2C%22lastName%22%3A%22Hyrenius-Wittsten%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yang%22%2C%22lastName%22%3A%22Su%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Minhee%22%2C%22lastName%22%3A%22Park%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%20M.%22%2C%22lastName%22%3A%22Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josef%22%2C%22lastName%22%3A%22Alavi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathaniel%22%2C%22lastName%22%3A%22Perry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Garrett%22%2C%22lastName%22%3A%22Montgomery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bin%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kole%20T.%22%2C%22lastName%22%3A%22Roybal%22%7D%5D%2C%22abstractNote%22%3A%22Short%20circuiting%20solid%20tumors%5CnTwo%20major%20hurdles%20in%20chimeric%20antigen%20receptor%20%28CAR%29%20T%20cell%20therapy%20for%20solid%20tumors%20are%20ensuring%20specificity%20to%20tumor%20cells%20without%20affecting%20healthy%20cells%20and%20avoiding%20tumor%20escape%20due%20to%20antigen%20loss.%20To%20address%20these%20challenges%2C%20Hyrenius-Wittsten%20et%20al.%20and%20Choe%20et%20al.%20developed%20synthetic%20Notch%20%28synNotch%29%5Cu2013CAR%20T%20cells%20targeting%20solid%20tumor%20antigens%20and%20used%20them%20to%20treat%20mouse%20models%20of%20mesothelioma%2C%20ovarian%20cancer%2C%20and%20glioblastoma.%20In%20both%20studies%2C%20the%20authors%20demonstrated%20that%20synNotch-CAR%20T%20cells%20were%20better%20at%20controlling%20tumors%20than%20traditional%20CAR%20T%20cells%20and%20did%20not%20result%20in%20toxicity%20or%20damage%20to%20healthy%20tissue.%20These%20results%20suggest%20that%20synNotch-CAR%20T%20cells%20may%20be%20an%20effective%20treatment%20strategy%20for%20solid%20tumors.%5CnThe%20first%20clinically%20approved%20engineered%20chimeric%20antigen%20receptor%20%28CAR%29%20T%20cell%20therapies%20are%20remarkably%20effective%20in%20a%20subset%20of%20hematological%20malignancies%20with%20few%20therapeutic%20options.%20Although%20these%20clinical%20successes%20have%20been%20exciting%2C%20CAR%20T%20cells%20have%20hit%20roadblocks%20in%20solid%20tumors%20that%20include%20the%20lack%20of%20highly%20tumor-specific%20antigens%20to%20target%2C%20opening%20up%20the%20possibility%20of%20life-threatening%20%5Cu201con-target%5C%2Foff-tumor%5Cu201d%20toxicities%2C%20and%20problems%20with%20T%20cell%20entry%20into%20solid%20tumor%20and%20persistent%20activity%20in%20suppressive%20tumor%20microenvironments.%20Here%2C%20we%20improve%20the%20specificity%20and%20persistent%20antitumor%20activity%20of%20therapeutic%20T%20cells%20with%20synthetic%20Notch%20%28synNotch%29%20CAR%20circuits.%20We%20identify%20alkaline%20phosphatase%20placental-like%202%20%28ALPPL2%29%20as%20a%20tumor-specific%20antigen%20expressed%20in%20a%20spectrum%20of%20solid%20tumors%2C%20including%20mesothelioma%20and%20ovarian%20cancer.%20ALPPL2%20can%20act%20as%20a%20sole%20target%20for%20CAR%20therapy%20or%20be%20combined%20with%20tumor-associated%20antigens%20such%20as%20melanoma%20cell%20adhesion%20molecule%20%28MCAM%29%2C%20mesothelin%2C%20or%20human%20epidermal%20growth%20factor%20receptor%202%20%28HER2%29%20in%20synNotch%20CAR%20combinatorial%20antigen%20circuits.%20SynNotch%20CAR%20T%20cells%20display%20superior%20control%20of%20tumor%20burden%20when%20compared%20to%20T%20cells%20constitutively%20expressing%20a%20CAR%20targeting%20the%20same%20antigens%20in%20mouse%20models%20of%20human%20mesothelioma%20and%20ovarian%20cancer.%20This%20was%20achieved%20by%20preventing%20CAR-mediated%20tonic%20signaling%20through%20synNotch-controlled%20expression%2C%20allowing%20T%20cells%20to%20maintain%20a%20long-lived%20memory%20and%20non-exhausted%20phenotype.%20Collectively%2C%20we%20establish%20ALPPL2%20as%20a%20clinically%20viable%20cell%20therapy%20target%20for%20multiple%20solid%20tumors%20and%20demonstrate%20the%20multifaceted%20therapeutic%20benefits%20of%20synNotch%20CAR%20T%20cells.%5CnSynNotch%20CAR%20circuits%20targeting%20specific%20solid%20tumor%20antigens%20enhance%20specificity%20and%20improve%20therapeutic%20efficacy%20by%20regulating%20T%20cell%20exhaustion.%5CnSynNotch%20CAR%20circuits%20targeting%20specific%20solid%20tumor%20antigens%20enhance%20specificity%20and%20improve%20therapeutic%20efficacy%20by%20regulating%20T%20cell%20exhaustion.%22%2C%22date%22%3A%222021%5C%2F04%5C%2F28%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1126%5C%2Fscitranslmed.abd8836%22%2C%22ISSN%22%3A%221946-6234%2C%201946-6242%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fstm.sciencemag.org%5C%2Fcontent%5C%2F13%5C%2F591%5C%2Feabd8836%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222021-04-29T05%3A42%3A07Z%22%7D%7D%5D%7D
Hyrenius-Wittsten, A., Su, Y., Park, M., Garcia, J. M., Alavi, J., Perry, N., Montgomery, G., Liu, B., & Roybal, K. T. (2021). SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Science Translational Medicine, 13(591). https://doi.org/10.1126/scitranslmed.abd8836 Cite